involvement of microRNA in the pathogenesis of COPD related sarcopenia

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08579
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53030:Respiratory medicine-related
• Research Institution: Nippon Sport Science University (2022); Jikei University School of Medicine (2020-2021)
• Principal Investigator: Hashimoto Mitsuo 日本体育大学, 体育学部, 教授 (00771742)
• Co-Investigator(Kenkyū-buntansha): 谷端 淳 東京慈恵会医科大学, 医学部, 講師 (00508426) ; 荒屋 潤 東京慈恵会医科大学, 医学部, 教授 (90468679)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 閉塞性肺疾患 / サルコペニア / Parkin / エクソソーム

Outline of Final Research Achievements

Exosomes from CSE-stimulated atrophic myotubes and from myotubes after contraction stimulation were suggested to have the effect of atrophying and hypertrophying myotubes, respectively. In addition, myotube contraction by electrical stimulation induced the expression of both Parkin and MHC, suggesting that Parkin is involved in the expression of MHC in experiments in which Parkin was knocked down.
The present study suggests that skeletal muscles of COPD patients secrete exosomes that differ from those of healthy subjects and may be involved in the pathogenesis of sarcopenia through intercellular communication. Parkin expression enhancement by exercise is expected to be a promising therapeutic strategy for sarcopenia, including COPD-associated sarcopenia.

Free Research Field

閉塞性肺疾患　サルコペニア

Academic Significance and Societal Importance of the Research Achievements

本研究では、COPD患者の骨格筋からは健常者の筋とは異なるエクソソームが分泌され、細胞間コミュニケーションによりサルコペニアの病態形成に関与する可能性が示唆され、また、運動によるParkinの発現増強は、COPD合併サルコペニアを含めたサルコペニアに対する有望な治療戦略として期待される事が示唆された。運動誘発のエクソソームの治療薬としての可能性が示唆され、今後のサルコペニア合併サルコペニア患者に対しての新たな治療薬の可能性を示唆した研究と考える。